<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Applications of trastuzumab are limited to <z:hpo ids='HP_0003002'>breast cancer</z:hpo> patients with high Her2-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We developed a T-cell receptor mimic (TCRm) monoclonal antibody (hereafter called RL1B) that targets the Her2-E75 <z:chebi fb="7" ids="16670">peptide</z:chebi> (residues 369-377)-HLA-A2 complex and examined its effects in Her2-expressing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: RL1B binding affinity was determined by surface plasmon resonance and specificity was demonstrated using Her2 antigen-positive and negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>Immunohistochemistry was used to assess binding to frozen sections of human <z:mp ids='MP_0002038'>carcinomas</z:mp> (n = 3) </plain></SENT>
<SENT sid="4" pm="."><plain>Antitumor activity mediated by RL1B and trastuzumab against Her2(+) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines was evaluated using the WST-1 cell viability assay and caspase-3 and poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase cleavage assays </plain></SENT>
<SENT sid="5" pm="."><plain>A xenograft mouse model (n = 6 per group) was used to assess RL1B antitumor activity </plain></SENT>
<SENT sid="6" pm="."><plain>Mechanisms of RL1B-mediated cytotoxicity were evaluated with confocal microscopy, flow cytometry, and histology </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> statistical tests were two-sided </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: RL1B bound with high specificity and affinity to the E75 <z:chebi fb="7" ids="16670">peptide</z:chebi>-HLA-A2 complex in <z:hpo ids='HP_0000001'>all</z:hpo> Her2(+) and HLA-A2(+) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines and human <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with control antibody, RL1B suppressed growth of low Her2-expressing <z:e sem="disease" ids="C1458155" disease_type="Neoplastic Process" abbrv="">breast tumors</z:e> in mice (mean volume, RL1B vs control = 241 mm(3) vs 1531 mm(3); P = .0109) and statistically significantly increased mouse survival (P = .0098) </plain></SENT>
<SENT sid="10" pm="."><plain>It <z:mp ids='MP_0010831'>reduced viability</z:mp> compared to control monoclonal antibody-treated cells and statistically significantly increased caspase 3 activation of <z:hpo ids='HP_0000001'>all</z:hpo> Her2(+) <z:mp ids='MP_0002038'>carcinoma</z:mp> cell lines tested, whereas trastuzumab induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> only in high Her2-expressing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="11" pm="."><plain>Mechanisms of RL1B cytotoxicity were associated with antibody internalization and intracellular signaling </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: The TCRm RL1B could be a new approach to immunotherapy of Her2-expressing <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>